Vor Biopharma reports 48-week Phase 3 data for telitacicept in Sjögren's disease from China

Vor Biopharma Inc.

Webcast held Oct 28, 2025 to discuss late-breaking 48-week Phase 3 results from China.
Trial evaluates telitacicept in primary Sjögren's disease; no specific efficacy/safety numbers provided in the filing text.
Stock may react to implied data direction, but actual results are not disclosed in this 8-K excerpt.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.